Hypersensitivity to PACAP-38 in Post-Traumatic Headache

• Status: Not yet recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim is to investigate whether signaling molecule PACAP-38 induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Danish Headache Center
• Treatments: Pituitary Adenylate Cyclase-Activating Polypeptide

Criteria

Inclusion Criteria:

• Age 18 to 65 years of age upon entry into screening

• History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)

• ≥ 4 monthly headache days on average across the 3 months prior to screening

• Provision of informed consent prior to initiation of any study-specific activities/procedures.

Exclusion Criteria:

• > 1 mild traumatic injury to the head

• History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)

• History of moderate or severe injury to the head

• History of whiplash injury

• History of craniotomy

• History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion

• The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior

• Female subjects of childbearing potential with a positive pregnancy test during any study visit

• Cardiovascular disease of any kind, including cerebrovascular diseases

• Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day

• Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)

• Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion

• Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start

• Baseline headache intensity of >3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)

• Baseline headache with migraine-like features or self-reported baseline headache that mimics the subjects' usual headache with migraine-like features